Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer
VC Jordan - Endocrine-related cancer, 2014 - erc.bioscientifica.com
Medullary thyroid carcinoma (MTC) is a rare malignancy originating from the calcitonin-
secreting parafollicular thyroid C cells. Approximately 75% of cases are sporadic …
secreting parafollicular thyroid C cells. Approximately 75% of cases are sporadic …
MicroRNAs as biomarkers in thyroid carcinoma
M Celano, F Rosignolo, V Maggisano… - … journal of genomics, 2017 - Wiley Online Library
Optimal management of patients with thyroid cancer requires the use of sensitive and
specific biomarkers. For early diagnosis and effective follow‐up, the currently available …
specific biomarkers. For early diagnosis and effective follow‐up, the currently available …
[HTML][HTML] Genetics of medullary thyroid cancer: an overview
G Accardo, G Conzo, D Esposito… - International journal of …, 2017 - Elsevier
Medullary thyroid carcinoma (MTC) represents 3–5% of thyroid cancers. 75% is sporadic
and 25% is the dominant component of the hereditary multiple endocrine neoplasia (MEN) …
and 25% is the dominant component of the hereditary multiple endocrine neoplasia (MEN) …
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
GI Manfredi, A Dicitore, G Gaudenzi, M Caraglia… - Endocrine, 2015 - Springer
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway is a central hub for the regulation of cell proliferation, apoptosis, cell cycle …
(mTOR) pathway is a central hub for the regulation of cell proliferation, apoptosis, cell cycle …
Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis
Advanced medullary thyroid cancers (MTCs) are now being treated with drugs that inhibit
receptor tyrosine kinases, many of which involved in angiogenesis. Response rates vary …
receptor tyrosine kinases, many of which involved in angiogenesis. Response rates vary …
MicroRNAs in the thyroid
M Boufraqech, J Klubo-Gwiezdzinska… - Best Practice & Research …, 2016 - Elsevier
MicroRNAs (miRNAs) are small non-coding RNA comprising approximately 19–25
nucleotides. miRNAs can act as tumour suppressors or oncogenes, and aberrant expression …
nucleotides. miRNAs can act as tumour suppressors or oncogenes, and aberrant expression …
Update on multiple endocrine neoplasia type 2: focus on medullary thyroid carcinoma
F Raue, K Frank-Raue - Journal of the Endocrine Society, 2018 - academic.oup.com
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant hereditary cancer
syndrome caused by missense gain-of-function mutations in the RET proto-oncogene on …
syndrome caused by missense gain-of-function mutations in the RET proto-oncogene on …
Dicing the disease with dicer: the implications of dicer ribonuclease in human pathologies
EI Theotoki, VI Pantazopoulou, S Georgiou… - International Journal of …, 2020 - mdpi.com
Gene expression dictates fundamental cellular processes and its de-regulation leads to
pathological conditions. A key contributor to the fine-tuning of gene expression is Dicer, an …
pathological conditions. A key contributor to the fine-tuning of gene expression is Dicer, an …
Classification of miRNA-related sequence variations
K Hrovatin, T Kunej - Epigenomics, 2018 - Taylor & Francis
miRNA regulome is whole set of regulatory elements that regulate miRNA expression or are
under control of miRNAs. Its understanding is vital for comprehension of miRNA functions …
under control of miRNAs. Its understanding is vital for comprehension of miRNA functions …